Clinical Trial Update: Neoadjuvant Nab-paclitaxel in Triple-negative or HER2-positive Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update studying neoadjuvant nab-paclitaxel in triple-negative or HER2-positive breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Nab-paclitaxel (paclitaxel protein-bound)

Snippet

Sponsor: Ruijin Hospital | Conditions: Breast Cancer, Triple Negative Breast Cancer | Phase 2 | Status: UNKNOWN